Top

Published in:

Open Access 01-06-2018 | Consensus paper and Guideline

Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management

Authors: Brigitte Decallonne, Emmanuel Bartholomé, Valérie Delvaux, Miguel D’haeseleer, Souraya El Sankari, Pierrette Seeldrayers, Bart Van Wijmeersch, Chantal Daumerie

Published in: Acta Neurologica Belgica | Issue 2/2018

Abstract

This paper deals with thyroid disease that can occur after treatment with alemtuzumab (humanized monoclonal anti-CD52) for relapsing–remitting multiple sclerosis (MS). The 5-year incidence of thyroid adverse events in phase 3 clinical trials is up to 40.7%. In most cases, the thyroid dysfunction is mild and easily manageable and only few serious thyroid adverse events have been reported. The need for patient education on the risk of thyroid dysfunction, as well as regular clinical and biochemical thyroid function screening is well described. However, practical clinical guidance in case of abnormal thyroid-related findings prior to or after alemtuzumab treatment is currently lacking. Therefore, a Belgian taskforce consisting of MS and thyroid experts was created in 2016, with the objective of issuing a clinical thyroid management algorithm based on available scientific evidence and personal experience with regard to alemtuzumab treatment-related thyroid adverse events.

Berger T, Elovaara I, Fredrikson S et al (2017) Alemtuzumab use in clinical practice: recommendations from European Multiple Sclerosis Experts. CNS Drugs 31:33–50. https://doi.org/10.1056/NEJMoa0802670 CrossRefPubMed

EMA—Lemtrada: EPAR—Product Information (2017) http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003718/human_med_001678.jsp&mid=WC0b01ac058001d124. Accessed 20 July 2017

CAMMS223 Trial Investigators, Coles AJ, Compston DA, Selmaj KW et al (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359(17):1786–1801. https://doi.org/10.1056/nejmoa0802670 CrossRef

Cohen JA, Coles AJ, Arnold DL, CARE-MS I investigators et al (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380:1819–1828. https://doi.org/10.1016/S0140-6736(12)61769-3 CrossRefPubMed

Coles AJ, Twyman CL, Arnold DL, CARE-MS II investigators et al (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380:1829–1839. https://doi.org/10.1016/S0140-6736(12)61768-1 CrossRefPubMed

Durelli L, De Mercanti SF, Cucci A et al (2016) Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation. ECTRIMS Online Library, Sep 15, p. 146466

Ruck T, Bittner S, Wiendl H, Meuth SG (2015) Alemtuzumab in multiple sclerosis: mechanism of action and beyond. Int J Mol Sci 16:16414–16439. https://doi.org/10.3390/ijms160716414 CrossRefPubMedPubMedCentral

Cox A, Thompson S, Jones J et al (2005) Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 35:3332–3342. https://doi.org/10.1002/eji.200535075 CrossRefPubMed

Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K (2017) Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. JAMA Neurol 74:961–969. https://doi.org/10.1001/jamaneurol.2017.0676 CrossRefPubMedPubMedCentral

10.

C Dayan, A Cuker, C LaGanke, on behalf of the CARE-MS Investigators et al (2016) Autoimmunity in patients treated With Alemtuzumab for relapsing-remitting multiple sclerosis: 5-year follow-up of the CARE-MS studies. ECTRIMS Online Library, Sep 16, p. 147015

11.

Selmaj K, Habek M, Bass A et al (2017) Efficacy and safety of alemtuzumab in patients with RRMSIs durable over 10 years: follow-up from the CAMMS223 study. Neurology 88(16), Supplement P5.338

12.

Havrdova E, Arnold D, Cohen J, Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy et al (2017) Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. Neurology 89:1107–1116. https://doi.org/10.1212/wnl.0000000000004313 CrossRefPubMedPubMedCentral

13.

Coles A, Cohen J, Fox E, CARE-MS II and CAMMS03409 Investigators et al (2017) Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. Neurology 89:1117–1126. https://doi.org/10.1212/wnl.0000000000004354 CrossRefPubMedPubMedCentral

14.

Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P (2014) Autoimmune thyroid disorders. Autoimmun Rev 14:174–180. https://doi.org/10.1016/j.autrev.2014.10.016 CrossRefPubMed

15.

Marrie RA, Reider N, Cohen J et al (2015) A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Mult Scler 21:282–293. https://doi.org/10.1177/1352458514564490 CrossRefPubMedPubMedCentral

16.

Pearce SH, Brabant G, Duntas LH et al (2013) 2013 ETA guideline: management of subclinical hypothyroidism. Eur Thyroid J 2:215–228. https://doi.org/10.1159/000356507 CrossRefPubMedPubMedCentral

17.

Garber JR, Cobin RH, Gharib H, American Association Of Clinical Endocrinologists And American Thyroid Association Taskforce On Hypothyroidism In Adults et al (2013) Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 22:1200–1235. https://doi.org/10.1089/thy.2012.0205 CrossRef

18.

Diana T, Krause J, Olivo PD et al (2017) Prevalence and clinical relevance of thyroid stimulating hormone receptor-blocking antibodies in autoimmune thyroid disease. Clin Exp Immunol 189:304–309. https://doi.org/10.1111/cei.12980 CrossRefPubMedPubMedCentral

19.

Biondi B, Bartalena L, Cooper DS et al (2015) The 2015 European Thyroid Association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J 4:149–163. https://doi.org/10.1159/000438750 CrossRefPubMedPubMedCentral

20.

Ross DS, Burch HB, Cooper DS et al (2016) 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26:1343–1421. https://doi.org/10.1089/thy.2016.0229 CrossRefPubMed

21.

Cooper DS (2005) Antithyroid drugs. N Engl J Med 352:905–917. https://doi.org/10.1056/NEJMra042972 CrossRefPubMed

22.

Bartalena L, Baldeschi L, Boboridis K, European Group on Graves’ Orbitopathy (EUGOGO) et al (2016) The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J 5:9–26. https://doi.org/10.1159/000443828 CrossRefPubMedPubMedCentral

23.

Pearce EN, Farwell AP, Braverman LE (2003) Thyroiditis. N Engl J Med 348:2646–2655. https://doi.org/10.1056/NEJMra021194 CrossRefPubMed

24.

Poppe K, Velkeniers B, Glinoer D (2008) The role of thyroid autoimmunity in fertility and pregnancy. Nat Clin Pract Endocrinol Metab 4:394–405. https://doi.org/10.1038/ncpendmet0846 CrossRefPubMed

25.

Alexander EK, Pearce EN, Brent GA et al (2017) Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid 27:315–389. https://doi.org/10.1089/thy.2016.0457 CrossRefPubMed

26.

Mahzari M, Arnaout A, Freedman MS (2015) Alemtuzumab induced thyroid disease in multiple sclerosis: a review and approach to management. Can J Neurol Sci 42:284–291. https://doi.org/10.1017/cjn.2015.48 CrossRefPubMed

27.

Habek M, Arnold D, Cohen J et al (2012) Thyroid autoimmunity in comparison of alemtuzumab and Rebif ^® efficacy in multiple sclerosis studies I and II. In: Proceedings of the 22nd meeting of the European Neurological Society (ENS), vol 259

28.

Coles AJ, Wing M, Smith S et al (1999) Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354:1691–1695. https://doi.org/10.1016/S0140-6736(99)02429-0 CrossRefPubMed

29.

Cossburn M, Pace AA, Jones J et al (2011) Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 77:573–579. https://doi.org/10.1212/WNL.0b013e318228bec5 CrossRefPubMed

30.

Senior PA, Arnold AL, Cohen JA et al (2016) Incidence and timing of thyroid adverse events in patients with RRMS treated with alemtuzumab. Neurology 86(16), Supplement P2.086

31.

Daniels GH, Vladic A, Brinar V et al (2014) Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab 99:80–89. https://doi.org/10.1210/jc.2013-2201 CrossRefPubMed

32.

Weetman AP (2014) Graves’ disease following immune reconstitution or immunomodulatory treatment: should we manage it any differently? Clin Endocrinol 80:629–632. https://doi.org/10.1111/cen.12427 CrossRef

33.

Rotondi M, Molteni M, Leporati P et al (2017) Autoimmune thyroid diseases in patients treated with alemtuzumab for multiple sclerosis: an example of selective anti-TSH-receptor immune response. Front Endocrinol (Lausanne). https://doi.org/10.3389/fendo.2017.00254 CrossRef

34.

Singer B, Hartung H, Margolin D et al (2015) Improvements in quality of life are maintained in alemtuzumab-treated RRMS patients who develop autoimmune adverse events: CARE-MS II. In: Annual meeting of the Consortium of Multiple Sclerosis Centers (CMSC)

35.

Ziemssen T, Selmaj K, Havrdova E et al (2015) Quality-of-life improvements with alemtuzumab are maintained in relapsing-remitting multiple sclerosis patients who develop thyroid adverse events in CARE-MS II. In: Meeting of the European Academy of Neurology (EAN)

36.

Vermersch P, Giovannoni G, Cohen J et al (2015) Quality-of-life improvements in patients with active relapsing-remitting multiple sclerosis are not impacted by acute infections after receiving alemtuzumab in CARE-MS II. ECTRIMS Online Library, Oct 9, p. 115894

37.

Wiersinga WM (2016) Clinical relevance of environmental factors in the pathogenesis of autoimmune thyroid disease. Endocrinol Metab (Seoul) 31:213–222. https://doi.org/10.3803/EnM.2016.31.2.213 CrossRef

Title: Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management
Authors: Brigitte Decallonne
Emmanuel Bartholomé
Valérie Delvaux
Miguel D’haeseleer
Souraya El Sankari
Pierrette Seeldrayers
Bart Van Wijmeersch
Chantal Daumerie
Publication date: 01-06-2018
Publisher: Springer International Publishing
Published in: Acta Neurologica Belgica / Issue 2/2018
Print ISSN: 0300-9009
Electronic ISSN: 2240-2993
DOI: https://doi.org/10.1007/s13760-018-0883-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Genetic Creutzfeldt–Jakob disease with an 8-year disease course

Dysphagia in myasthenia gravis: the tip of the Iceberg

Hypoglossal nerve involvement in Lewis–Sumner syndrome: a case report

Smaller caliber of the internal carotid artery in patients with ipsilateral aplasia of the A1 segment of the anterior cerebral artery: a study with CTA

Uncommon and/or bizarre features of dementia: Part III

Long-term disability and progression in spinal onset multiple sclerosis